AstraZeneca and Government of Canada announce agreement to supply up to 20 million doses of the AZD1222 COVID-19 vaccine

AstraZeneca has signed an agreement with the Government of Canada for the supply of its COVID-19 vaccine candidate, AZD1222. The agreement will supply up to 20 million doses of AZD1222 to the Government of Canada, with deliveries in 2021, should clinical trials prove to be successful.

AstraZeneca is currently conducting clinical trials to assess the safety and efficacy of AZD1222, in collaboration with Oxford University, to protect against COVID-19.

Today’s agreement will mean that AZD1222 can be made available to millions of Canadians. AstraZeneca will continue to work with regulatory authorities around the world, including Health Canada, as we continue to build our efficacy and safety data for AZD1222. The Company’s commitment to the safety and well-being of those participating in our trials, and the millions we hope will benefit from the vaccine in the future, is of paramount importance.

“We are proud of the work that AstraZeneca is doing at the forefront of science and with the rest of the biopharmaceutical industry to help save lives and mitigate the devastating impacts of this global pandemic,” said Jane Chung, President, AstraZeneca Canada. “Today’s announcement with the Government of Canada reinforces our commitment to ‘doing the right thing’ – addressing the pandemic by advancing our vaccine candidate to help save lives during this health crisis and support the recovery of economies as quickly as possible.”

AstraZeneca continues to engage with governments, multilateral organizations and partners around the world to ensure broad and equitable access to the vaccine, should clinical trials prove successful. The agreement with the Government of Canada takes the global supply capacity towards three billion doses of the vaccine.

AZD1222

AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.

About AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, the company employs approximately 900 employees across the country and our headquarters are located in Mississauga, Ontario.

For more information, please visit www.astrazeneca.com.

Media Contact

Carlo Mastrangelo
Director, Communications & Sustainability, AstraZeneca Canada
Carlo.mastrangelo@astrazeneca.com